We enable nucleic acid labeling bioconjugation
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
product_variation
We enable nucleic acid labeling bioconjugation
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
product_variation
buy products
We enable nucleic acid labeling bioconjugation

Author Archive

  • 14
    Oct

    BIO-EUROPE 2022

    We are excited to meet you at the BIO-Europe 2022 in Leipzig on Oct. 24-26, 2022. Please contact our CEO Dr. Thomas Frischmuth for more

    MORE →

  • 9
    Jul

    Dr. Frischmuth gives an interview about our vaccine development

    The mRNA vaccines have the great advantage that they can be developed very quickly and in a modular fashion. We can even change the genes

    MORE →

  • 9
    Jul

    Milestone for BioNTech

    325 Million USD for further development of its cancer immunotherapy. Learn more at:

    MORE →

  • 22
    Apr

    Eli Lilly and Avidity Biosciences announce licensing & research cooperation

    on combined monoclonal antibodies and oligonucleotide-based therapies for potential new medicines in immunology and other select indications. Read more here:

    MORE →